NZ626951A - Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents - Google Patents

Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents

Info

Publication number
NZ626951A
NZ626951A NZ626951A NZ62695113A NZ626951A NZ 626951 A NZ626951 A NZ 626951A NZ 626951 A NZ626951 A NZ 626951A NZ 62695113 A NZ62695113 A NZ 62695113A NZ 626951 A NZ626951 A NZ 626951A
Authority
NZ
New Zealand
Prior art keywords
amino
preparation
compounds
lactam compounds
thiazol
Prior art date
Application number
NZ626951A
Other languages
English (en)
Inventor
Burkhard Klenke
Irith Wiegand
Guido Schiffer
Heike Broetz-Oesterhelt
Samarendra N Maiti
Jehangir Khan
Andhe Reddy
Zhixiang Yang
Mostafa Hena
Guofeng Jia
Ou Ligong
Hong Liang
Judy Yip
Chuanjun Gao
Sabiha Tajammul
Rahim Mohammad
Ganguli Biswajeet
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of NZ626951A publication Critical patent/NZ626951A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ626951A 2012-01-24 2013-01-23 Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents NZ626951A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12152279 2012-01-24
PCT/EP2013/051217 WO2013110643A1 (en) 2012-01-24 2013-01-23 Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents

Publications (1)

Publication Number Publication Date
NZ626951A true NZ626951A (en) 2016-03-31

Family

ID=47603723

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ626951A NZ626951A (en) 2012-01-24 2013-01-23 Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents

Country Status (42)

Country Link
US (2) US9556165B2 (OSRAM)
EP (1) EP2806873B1 (OSRAM)
JP (1) JP5869701B2 (OSRAM)
KR (1) KR102036393B1 (OSRAM)
CN (1) CN104203237A (OSRAM)
AP (1) AP2014007880A0 (OSRAM)
AR (1) AR089796A1 (OSRAM)
AU (1) AU2013211575B2 (OSRAM)
BR (1) BR112014017968A8 (OSRAM)
CA (1) CA2862338C (OSRAM)
CL (1) CL2014001956A1 (OSRAM)
CO (1) CO7101240A2 (OSRAM)
CU (1) CU24273B1 (OSRAM)
CY (1) CY1117955T1 (OSRAM)
DK (1) DK2806873T3 (OSRAM)
EA (1) EA027126B1 (OSRAM)
EC (1) ECSP14010249A (OSRAM)
ES (1) ES2592403T3 (OSRAM)
HR (1) HRP20161171T1 (OSRAM)
HU (1) HUE030452T2 (OSRAM)
IL (1) IL233805A (OSRAM)
IN (1) IN2014MN01640A (OSRAM)
LT (1) LT2806873T (OSRAM)
MA (1) MA35905B1 (OSRAM)
ME (1) ME02532B (OSRAM)
MX (1) MX346602B (OSRAM)
MY (1) MY173843A (OSRAM)
NZ (1) NZ626951A (OSRAM)
PE (1) PE20142345A1 (OSRAM)
PH (1) PH12014501671B1 (OSRAM)
PL (1) PL2806873T3 (OSRAM)
PT (1) PT2806873T (OSRAM)
RS (1) RS55210B1 (OSRAM)
SG (1) SG11201403930XA (OSRAM)
SI (1) SI2806873T1 (OSRAM)
SM (1) SMT201600354B (OSRAM)
TN (1) TN2014000297A1 (OSRAM)
TW (1) TWI659953B (OSRAM)
UA (1) UA110880C2 (OSRAM)
UY (1) UY34585A (OSRAM)
WO (1) WO2013110643A1 (OSRAM)
ZA (1) ZA201405057B (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160326157A1 (en) * 2014-01-06 2016-11-10 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
MA39777B1 (fr) 2014-03-24 2019-03-29 Novartis Ag Composes organiques de la famille des monobactams pour le traitement d'infections bactériennes
CN105175335B (zh) * 2015-08-13 2017-11-03 南阳师范学院 一种3‑(3,3‑二氯烯丙氧基)‑1‑甲基吡唑‑5‑甲酰胺衍生物及其制备方法
RU2754180C2 (ru) * 2015-09-23 2021-08-30 Новартис Аг Соли и твердые формы монобактамного антибиотика
EP3390357B1 (en) * 2015-12-15 2021-11-10 Merck Sharp & Dohme Corp. Biaryl monobactam compounds for the treatment of bacterial infections
KR102408800B1 (ko) * 2016-03-07 2022-06-13 머크 샤프 앤드 돔 코포레이션 비시클릭 아릴 모노박탐 화합물 및 박테리아 감염의 치료를 위한 그의 사용 방법
CN107641119B (zh) 2016-07-21 2019-11-08 中国科学院上海药物研究所 单环β-内酰胺-铁载体轭合物及其制备方法和用途
SG11201900669WA (en) 2016-08-26 2019-03-28 Codexis Inc Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
EP3541382A1 (en) 2016-11-18 2019-09-25 AiCuris Anti-infective Cures GmbH Liposomal formulations of amidine substituted beta-lactam compounds for use in the treatment of bacterial infections
US20190365720A1 (en) 2016-11-18 2019-12-05 Aicuris Anti-Infective Cures Gmbh Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
US20200093814A1 (en) * 2016-12-21 2020-03-26 Aicuris Gmbh & Co. Kg Combination therapy with amidine substituted beta-lactam compounds and beta-lactamase inhibitors for infections with antibiotic resistant bacterial strains
AU2018304841A1 (en) 2017-07-18 2020-02-06 Bayer Aktiengesellschaft Substituted 3-heteroaryloxy-1H-pyrazoles and salts thereof and their use as herbicidal active substances
AR112464A1 (es) 2017-07-28 2019-10-30 Aicuris Anti Infective Cures Gmbh Forma cristalina de ácido (2s)-2-[[(z)-[1-(2-amino-4-tiazolil)-2-[[(3s)-2,2-dimetil-4-oxo-1-(sulfoxi)-3-azetidinil]amino]-2-oxoetiliden]amino]oxi]-3-[4-[imino[(3r)-3-piperidinilamino]metil]fenoxi]-propanoico
JP7235718B2 (ja) 2017-08-02 2023-03-08 ノバルティス アーゲー モノバクタム系抗生物質およびその中間体を製造するための化学的方法
KR102425959B1 (ko) * 2017-10-02 2022-07-27 머크 샤프 앤드 돔 코포레이션 박테리아 감염의 치료를 위한 크로만 모노박탐 화합물
BR112020006594A2 (pt) * 2017-10-02 2020-12-15 Arixa Pharmaceuticals, Inc. Derivados de aztreonam e usos dos mesmos
US11459323B2 (en) 2018-01-29 2022-10-04 Medshine Discovery Inc. Monocyclic β-lactam compound for treating bacterial infection
CN112771040B (zh) * 2018-11-13 2022-10-18 南京圣和药业股份有限公司 单环内酰胺化合物及其应用
CN113227088B (zh) 2018-12-18 2022-05-31 南京明德新药研发有限公司 单环β-内酰胺化合物在制药中的应用
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
CN114828850B (zh) 2019-12-19 2024-08-13 深圳嘉科生物科技有限公司 化合物在制药中的应用
CN111253405B (zh) * 2020-03-20 2022-12-16 南京安伦化工科技有限公司 一种比阿培南中间体的制备方法
CN113754651B (zh) * 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
CN111592536B (zh) * 2020-06-04 2023-11-03 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺化合物及其制备方法和应用
EP4165039B1 (en) * 2020-07-16 2024-08-21 Ningxia Academy of Agriculture and Forestry Sciences Novel monobactam compounds, their preparation and use as antibacterial agents
CN114728953B (zh) * 2020-08-06 2024-04-09 宁夏农林科学院 β-内酰胺类化合物,及其制备方法以及其作为抗菌素的应用
CN112079791A (zh) * 2020-08-21 2020-12-15 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用
CN111909067B (zh) * 2020-08-28 2022-03-15 浙江凯普化工有限公司 一种d-青霉胺的有机全合成方法
WO2023082055A1 (zh) * 2021-11-09 2023-05-19 中国医学科学院医药生物技术研究所 包含β-内酰胺类化合物的药物组合物及其用途
JP7671398B2 (ja) * 2021-11-18 2025-05-01 メルク・シャープ・アンド・ドーム・エルエルシー クロマンアミジンモノバクタム抗生物質
AU2022391635B2 (en) 2021-11-18 2025-10-02 Merck Sharp & Dohme Llc Chromane amidine monobactam antibiotics
CN118255695B (zh) * 2024-02-26 2025-03-14 广州艾奇西医药科技有限公司 一种β-内酰胺类化合物的中间体的纯化方法和制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794886A (fr) * 1972-02-22 1973-08-02 Pfizer Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques
DE2458973A1 (de) * 1974-12-13 1976-06-16 Hoechst Ag Acylaminopenicillansaeuren und verfahren zu ihrer herstellung
DE2749265A1 (de) 1977-11-03 1979-05-10 Linde Ag Verfahren zur biologischen reinigung von abwasser
ZA806977B (en) * 1979-11-19 1981-10-28 Fujisawa Pharmaceutical Co 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
JPS58210061A (ja) * 1982-05-31 1983-12-07 Takeda Chem Ind Ltd 1−スルホ−2−オキソアゼチジン誘導体、その製造法および用途
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
NZ205642A (en) 1982-10-06 1986-08-08 Squibb & Sons Inc Beta-lactams and pharmaceutical compositions
US4638060A (en) 1985-04-29 1987-01-20 E. R. Squibb & Sons, Inc. O-sulfated spiro β-lactam hydroxamic acids
JPH01290674A (ja) 1988-04-04 1989-11-22 E R Squibb & Sons Inc アゼチジニル誘導体
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
CA2024282A1 (en) 1989-09-21 1991-03-22 Peter H. Ermann Heterocyclic hydrazide derivatives of monocyclic beta-lactam antibiotics
ZA918014B (en) 1990-11-05 1992-07-29 Squibb & Sons Inc Heteroaroyl derivatives of monocyclic beta-lactam antibiotics
US5250691A (en) 1991-09-09 1993-10-05 E. R. Squibb & Sons, Inc. Heteroaryl derivatives of monocyclic beta-lactam antibiotics
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
BR0113861A (pt) * 2000-09-14 2004-01-27 Pantherix Ltd Derivados de ácidos 3-(heteroaril acetamido)-2-oxo-azetidina-1-sulfÈnicos como agentes antibacterianos
WO2005070874A1 (en) 2004-01-27 2005-08-04 Merck Frosst Company Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
CN101511187B (zh) 2005-09-23 2012-07-04 株式会社爱慕知科学 哌啶和哌嗪衍生物
SI1965798T1 (sl) 2005-12-07 2012-01-31 Basilea Pharmaceutica Ag Uporabni monobaktamski antibiotiki
AU2007216034B2 (en) 2006-02-14 2011-08-04 Kumiai Chemical Industry Co., Ltd. Process for production of 5-alkoxy-4-hydroxymethylpyrazole compound
JP2009530228A (ja) 2006-03-16 2009-08-27 アステラス製薬株式会社 セフェム化合物および抗菌薬としての利用
NZ579375A (en) * 2007-03-23 2012-02-24 Basilea Pharmaceutica Ag Combination medicaments for treating bacterial infections
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
MX2011006541A (es) 2008-12-19 2011-07-20 Pfizer Monocarbamas.

Also Published As

Publication number Publication date
HRP20161171T1 (hr) 2016-11-04
SMT201600354B (it) 2016-11-10
IL233805A0 (en) 2014-09-30
MA35905B1 (fr) 2014-12-01
KR20140114390A (ko) 2014-09-26
TN2014000297A1 (en) 2015-12-21
US9782390B2 (en) 2017-10-10
RS55210B1 (sr) 2017-01-31
HK1203389A1 (zh) 2015-10-30
CN104203237A (zh) 2014-12-10
TWI659953B (zh) 2019-05-21
US9556165B2 (en) 2017-01-31
SG11201403930XA (en) 2014-08-28
DK2806873T3 (en) 2016-08-29
AR089796A1 (es) 2014-09-17
CA2862338A1 (en) 2013-08-01
IL233805A (en) 2016-06-30
PT2806873T (pt) 2016-09-23
CL2014001956A1 (es) 2014-11-07
CU24273B1 (es) 2017-08-08
JP2015504907A (ja) 2015-02-16
PL2806873T3 (pl) 2016-12-30
HUE030452T2 (en) 2017-05-29
PH12014501671B1 (en) 2020-02-28
MY173843A (en) 2020-02-24
LT2806873T (lt) 2016-10-10
EP2806873A1 (en) 2014-12-03
BR112014017968A8 (pt) 2017-07-11
CU20140090A7 (es) 2014-12-26
CA2862338C (en) 2019-04-16
PE20142345A1 (es) 2015-01-09
ME02532B (me) 2017-02-20
AU2013211575B2 (en) 2017-03-02
EA201400838A1 (ru) 2014-12-30
US20150045340A1 (en) 2015-02-12
IN2014MN01640A (OSRAM) 2015-05-22
ZA201405057B (en) 2017-09-27
MX2014008915A (es) 2014-08-26
EA027126B1 (ru) 2017-06-30
WO2013110643A1 (en) 2013-08-01
TW201343643A (zh) 2013-11-01
ECSP14010249A (es) 2015-12-31
KR102036393B1 (ko) 2019-10-24
JP5869701B2 (ja) 2016-02-24
EP2806873B1 (en) 2016-06-15
US20170100379A1 (en) 2017-04-13
CY1117955T1 (el) 2017-05-17
UA110880C2 (uk) 2016-02-25
PH12014501671A1 (en) 2014-11-10
AU2013211575A1 (en) 2014-07-24
BR112014017968A2 (OSRAM) 2017-06-20
ES2592403T3 (es) 2016-11-30
CO7101240A2 (es) 2014-10-31
SI2806873T1 (sl) 2016-10-28
UY34585A (es) 2013-09-02
MX346602B (es) 2017-03-24
AP2014007880A0 (en) 2014-08-31

Similar Documents

Publication Publication Date Title
NZ626951A (en) Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents
PH12014502224A1 (en) Heterobicyclic compounds as beta-lactamase inhibitors
BR112013028813A2 (pt) derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
NZ628527A (en) 2-substituted cephem compounds
BR112015003592A2 (pt) derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
EA201890150A1 (ru) 3-тетразолил-бензол-1,2-дисульфонамидные производные в качестве ингибиторов металло-бета-лактамазы
MX2018010878A (es) Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
EA201201378A1 (ru) Определенные аминопиримидины, композиции на их основе и способы их использования
MD4582B1 (ro) Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei
SA520411571B1 (ar) مركبات كرومان مونوباكتام لعلاج العدوى البكتيرية
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
EA201500544A1 (ru) НОВЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНТИБАКТЕРИАЛЬНЫХ АГЕНТОВ И ИНГИБИТОРОВ β-ЛАКТАМАЗ
EA201100613A1 (ru) Конденсированные, спироциклические гетероароматические соединения для лечения бактериальных инфекций
WO2013106761A3 (en) Antimicrobial agents
BR112013031402A2 (pt) derivados de hidantoína como inibidores de kv3
GEP20156370B (en) Fluoro-pyridinone derivatives useful as antibacterial agents
MX339455B (es) Inhibidores de pirimidina y topoisomerasa iv.
EA201070592A1 (ru) Ингибиторы пептиддеформилазы
EA201590021A1 (ru) Новые замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса
MX2013008161A (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea.
BR112014012983A2 (pt) derivados de pirrol
WO2011160020A3 (en) Carbapenem antibacterials with gram-negative activity
MX2013008163A (es) Formas solidas de inhibidor de girasa (r)-1-etil-3-[5-[2-(1-hidrox i-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzim idazol-2-il]urea.
HK1222339A1 (zh) 金属-β-内酰胺酶的抑制剂
TN2014000166A1 (en) N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2018 BY DENNEMEYER + CO

Effective date: 20161227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2019 BY DENNEMEYER + CO

Effective date: 20171218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2020 BY DENNEMEYER + CO

Effective date: 20181220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2021 BY DENNEMEYER + CO

Effective date: 20191220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2022 BY DENNEMEYER + CO.

Effective date: 20210111

LAPS Patent lapsed